- Report
- April 2020
- 120 Pages
Global
From €3539EUR$3,660USD£3,019GBP
- Report
- August 2020
- 260 Pages
Global
From €10631EUR$10,995USD£9,071GBP
- Report
- April 2020
- 204 Pages
Global
From €10631EUR$10,995USD£9,071GBP
- Report
- December 2018
- 153 Pages
Global
From €3379EUR$3,495USD£2,883GBP
- Drug Pipelines
- September 2020
- 57 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- January 2024
- 85 Pages
Global
From €3500EUR$3,878USD£3,091GBP
- Report
- November 2022
- 79 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- October 2022
- 286 Pages
Global
From €2417EUR$2,500USD£2,062GBP
- Report
- July 2022
- 67 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- June 2022
- 32 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Drug Pipelines
- November 2019
- 57 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- May 2023
- 251 Pages
Global
From €5540EUR$5,730USD£4,727GBP
- Report
- September 2023
- 160 Pages
Global
From €2900EUR$2,999USD£2,474GBP
Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders.
Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more
